← Evidence map

ArticleBlood cancer journal2026

Is Less "Sufficient" and "Safe" in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma.

Sumeet Mirgh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papercites it

Is Less "Sufficient" and "Safe" in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma. | OpenQuestion